Theoretical Basis, Experimental Design, and Computerized Simulation of Synergism and Antagonism in Drug Combination Studies

By T. Chou. 2006

5,016 citations recorded by the source corpus.

Subfields: Computational Theory and Mathematics, Oncology, Organic Chemistry

How researchers see this paper

The researchers whose trusted networks rank it highest, strongest advocate first. Every researcher gets a different order.

In Computational Theory and Mathematics

In Oncology

In Organic Chemistry

Citations in the corpus

Prediction of synergistic anti-cancer drug combinations based on drug target network and drug induced gene expression profiles (2017, background): “Synergistic drug combination therapy could be an ideal solution [4].”
Mechanisms of drug combinations: interaction and network perspectives (2009, background): “A combination is pharmacodynamically synergistic, additive or antagonistic if the effect is greater than, equal to, or less than the summed effects of the partner drug”
DeepSynergy: predicting anti-cancer drug synergy with Deep Learning (2017, background): “…areas, such as cancer (Al-Lazikani et al. , 2012), viral disease including human immunodeficiency virus (HIV) and hepatitis C virus infections (Clercq, 2007) as well as fungal (Chen et al. , 2016; Groll and Tragiannidis, 2009) and bacterial infections (Tamma et al. , 2012; Worthington and…”
Guidelines for the welfare and use of animals in cancer research (2010, background): “…models Long time frame and variability in tumour development Surgically-induced tumours Oesophago-gastroduodenal anastomosis model of oesophageal carcinogenesis (Chen et al, 1999) Can model malignant progression or metastatic spread High level of skill required for initiation Incidence may not be…”
An Analytics Approach to Designing Combination Chemotherapy Regimens for Cancer (2016, methodology): “Molecular simulation is a well-developed methodology for identifying synergism in drug combinations (Chou 2006), and virtual clinical trials, which rely on pharmacodynamic and pharmacokinetic models to analyze different drug combinations, can also be used to suggest new treatments (Kleiman et al.…”
Searching for Drug Synergy in Complex Dose–Response Landscapes Using an Interaction Potency Model (2015, background): “However,itonlyallowsforaman-ualinput of dose – response datafor onedrug combination ata time, and thus becomes quickly unfeasible for analyzing large-scale drug screening data which typically consists of hundreds of combinations.”
Combining genomic and network characteristics for extended capability in predicting synergistic drugs for cancer (2015, positive): “The drugs in the remaining 17 pairs were purchased and experimentally validated using the human MCF7 cell line (Supplementary Note 1).”
Strongly enhanced antitumor activity of trastuzumab and pertuzumab combination treatment on HER2-positive human xenograft tumor models. (2009, methodology): “The synergistic action of trastuzumab and pertuzumab combination treatment was previously shown in vitro (30) using the calculation of the combination index as outlined by Chou and Talalay (35, 36).”
Drug combination studies and their synergy quantification using the Chou-Talalay method. (2010, methodology): “With these parameters [(m)1, (Dm)1 and (m)2, (Dm)2] available, we could determine whether there is synergism or antagonism, quantitatively, by using the CI equation, even for only a single combination data point (1).”
Systematic prediction of drug combinations based on clinical side-effects (2014, background): “T he use of multiple drugs with different mechanisms or modes of action may treat the disease more effectively 1–3 . diseases The traditional ‘‘one drug – one target – one disease’’ approach has been successfully used to develop drugs.”